http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Ardelyx Announces the First Recipients of Derek Forfang Patient Advocate Award
-
Ardelyx (ARDX) Announces Tenapanor Approved in China for Hyperphosphatemia
-
Tenapanor Approved in China for Hyperphosphatemia
-
Ardelyx to Participate in Upcoming Investor Conferences
-
Ardelyx Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
-
Ardelyx to Present at the TD Cowen 45th Annual Health Care Conference
-
Ardelyx to Report Full Year and Fourth Quarter 2024 Financial Results on February 20, 2025
-
Ardelyx (ARDX) Provides Update on Increasing Commercial Momentum and 2025 Strategic Priorities
-
Ardelyx Provides Update on Increasing Commercial Momentum and 2025 Strategic Priorities
-
Ardelyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference
-
Ardelyx to Participate at the Piper Sandler 36th Annual Healthcare Conference
-
Ardelyx (ARDX) Responds to District Court Decision Granting Motion to Dismiss
-
Ardelyx Responds to District Court Decision Granting Motion to Dismiss
-
Ardelyx Responds to District Court Decision Granting Motion to Dismiss
-
Ardelyx to Participate at the 2024 Jefferies London Healthcare Conference
-
Ardelyx Reports Third Quarter 2024 Financial Results and Provides Business Update
-
Ardelyx Presents Results from its IBS in America 2024 Supplemental Survey at the American College of Gastroenterology’s (ACG) Annual Meeting
-
Ardelyx (ARDX) Reports Additional Data Supporting First-In-Class XPHOZAH
-
Ardelyx Shares Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) at the American Society of Nephrology’s Kidney Week
-
Ardelyx (ARDX) Announces Launch of Gut Matters
-
Ardelyx Announces Launch of Gut Matters: Discoveries and Innovations, a New Podcast for the IBS-C Patient Community
-
Ardelyx Announces the Derek Forfang Patient Advocate Award to Recognize Advocates for the Chronic Kidney Disease Community
-
Ardelyx to Report Third Quarter 2024 Financial Results on October 31, 2024
-
Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the American Society of Nephrology’s Kidney Week
-
Ardelyx (ARDX) Announces Publication of a Review Article Exploring the Patient Burden and Therapeutic Landscape of IBS-C in the U.S. in Clinical and Experimental Gastroenterology
-
Ardelyx Announces Publication of a Review Article Exploring the Patient Burden and Therapeutic Landscape of IBS-C in the U.S. in Clinical and Experimental Gastroenterology
-
Ardelyx to Participate at the 2024 Cantor Global Healthcare Conference
-
Ardelyx (ARDX) Appoints Eric Foster as Chief Commercial Officer
-
Ardelyx Appoints Experienced Biopharma Executive, Eric Foster, as Chief Commercial Officer
-
Ardelyx Reports Second Quarter 2024 Financial Results and Provides Business Update
-
Ardelyx Announces Publication of Two Plain Language Summaries from XPHOZAH® (tenapanor) Clinical Trials in Current Medical Research and Opinion
-
Ardelyx to Report Second Quarter 2024 Financial Results on August 1, 2024
-
Ardelyx, AAKP and NMQF File Lawsuit to Protect Dialysis Patient Choice and Timely Access to Clinically Meaningful Medicines
-
Ardelyx (ARDX) to Not File for TDAPA
-
To Preserve Patient Access to XPHOZAH®, Ardelyx Chooses Not to File for TDAPA
-
Ardelyx Presents Additional Data Detailing Educational Needs Related to IBS-C Management Across Healthcare Disciplines
-
Ardelyx, Inc. Reports Employment Inducement Grants
-
Ardelyx to Participate at the 2024 Jefferies Global Healthcare Conference
-
Ardelyx Presents Additional Data at the 2024 Digestive Disease Week Conference on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults
-
Ardelyx Presents Additional Data at the NKF 2024 Spring Clinical Meetings on XPHOZAH® (tenapanor)
-
Ardelyx, Inc. Reports Employment Inducement Grants
-
Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week Conference
-
Ardelyx Reports First Quarter 2024 Financial Results and Provides Business Update
-
Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the National Kidney Foundation 2024 Spring Clinical Meetings
-
Ardelyx to Report First Quarter 2024 Financial Results on May 2, 2024
-
Ardelyx, Inc. Reports Employment Inducement Grants
-
Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate Development and Strategy
-
Ardelyx, Inc. Reports Employment Inducement Grants
-
Ardelyx to Participate at the Cowen 44th Annual Health Care Conference
-
Ardelyx Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

